Asset Details
Do you wish to reserve the book?
Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy
Do you wish to request the book?
Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy
2014
Overview
Background
Peritoneal carcinomatosis (PC) is an unmet medical need. Despite recent improvements, systemic chemotherapy has limited efficacy. We report the first application of intraperitoneal chemotherapy as a pressurized aerosol in human patients.
Methods
Three end-stage patients with advanced PC from gastric, appendiceal, and ovarian origin were treated as a compassionate therapy. All patients had received previous systemic chemotherapy. A pressurized aerosol of CO
2
loaded with doxorubicin 1.5 mg/m
2
and cisplatin 7.5 mg/m
2
(pressurized intraperitoneal aerosol chemotherapy, PIPAC) was applied into the abdomen for 30 min at a pressure of 12 mmHg and a temperature of 37 °C.
Results
No side-effects >2 CTCAE were observed, and the procedures were well tolerated. Early hospital discharge was possible (days 2–5). Nuclear presence of doxorubicin was documented throughout the peritoneum, reaching high local concentration (≤4.1 μmol/g) and plasma concentration was low (4.0–6.2 ng/ml). PIPAC created no significant adhesions, could be repeated, and was applied 6×, 4×, and 2×. Two patients showed a complete and one a partial histological remission. Mean survival after the first PIPAC was 288 days. One patient is alive after 567 days.
Conclusions
PIPAC shows superior pharmacological properties with high local concentration and low systemic exposure. PIPAC can induce regression of PC in chemoresistant tumors, using 10 % of a usual systemic dose.
Publisher
Springer US,Springer Nature B.V
Subject
/ Aerosols
/ Aged
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Appendiceal Neoplasms - drug therapy
/ Appendiceal Neoplasms - mortality
/ Appendiceal Neoplasms - pathology
/ Female
/ Humans
/ Male
/ Medicine
/ Oncology
/ Ovarian Neoplasms - drug therapy
/ Ovarian Neoplasms - mortality
/ Ovarian Neoplasms - pathology
/ Peritoneal Neoplasms - drug therapy
/ Peritoneal Neoplasms - mortality
/ Peritoneal Neoplasms - secondary
/ Pressure
/ Stomach Neoplasms - drug therapy
/ Stomach Neoplasms - mortality
/ Stomach Neoplasms - pathology
/ Surgery
